Could cause temporary or reversible harm; serious harm is unlikely.
Failed Impurities/Degradation Specifications: This recall is due to out of specification for impurities test results obtained during stability testing for Lansoprazole.
| Distributed by / for | Teva Pharmaceuticals USA |
| NDC | 0093-8055-78 |
| Full product label | triple therapy, LANSOPRAZOLE DR Capsules USP 30mg, CLARITHROMYCIN Tablets USP 500mg, AMOXICILLIN Capsules USP 500mg, 8 count Blister Pack Lansoprazole DR Capsules USP & Clarithromycin Tablets USP, MANUFACTURED Israel for Teva Pharmaceuticals USA, Sellersville, PA 18960, Amoxicillin Capsules USP manufactured in Canada, for Teva Pharmaceuticals USA, Sellersville, PA 18960. NDC# 0093-8055-78 |
| Recalling firm | Teva Pharmaceuticals USA |
| Distribution | Nationwide |
| Quantity | 89,215 blister pack |
| Recall initiated | 2014-04-01 |
| Report date | 2014-08-06 |
| Recall completed | 2014-11-20 |
| Recall number | D-1499-2014 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Horsham PA United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗